Dr.Max the largest pharmacy network in Central Europe is becoming the number one pharmaceutical operator in the Romanian market and among the top 4 retail pharmacy chains in Europe

The A&D Pharma Group will have a new owner. The acquisition of the group will be a significant boost to Dr.Max, a company operating also in the Czech, Slovak, Polish, Serbian and Italian markets. The transaction is still subject to approval by the antimonopoly authority and its value will not be disclosed.

The international pharmacy chain Dr.Max has concluded a purchase contract with A&D Pharma via GLEBI HOLDINGS PLC. A&D Pharma owns Sensiblu and Punkt pharmacy networks, Mediplus wholesale company in Romania and A&D Pharma Marketing and Sales – one of the biggest marketing and sales pharmaceutical platform operating in CEE. Dr.Max already operates 31 pharmacies in Romania following the acquisition of Arta pharmacies in June this year. With its total number of 631 pharmacies, the leading full-line wholesaler business, the Marketing&Sales service provider and more than 4,500 people employed, Dr.Max will become number one in the Romanian pharmaceutical market; “with the acquisition of A&D Pharma, Dr.Max is further strengthening its presence in Central Europe and is clearly expanding its leading position as an Omnichannel retail healthcare provider in Europe”, said Dr.Max CEO Leonardo Ferrandino.

“We do everything in our power to ensure that our patients trust us completely,” Leonardo Ferrandino says, and adds: “we have achieved the market leader position for our pharmacies, in particular in the Czech Republic, Slovakia and Poland, mainly by offering highly professional services, top quality products and easy access. Our company utilises top professional staff to serve our patients and strive to fulfil our patients´real needs.”

Dr.Max operates more than 1,300 pharmacies in Central and Eastern Europe with total sales of EUR 1.25 billion. Dr.Max is the first choice for customers in many countries and this makes it the strongest pharmacy brand in the Central European market. The acquisition of the A&D Pharma Group will step up the sales of Dr.Max to more than EUR 2.3 billion and the company will become a Europewide player employing more than 12,000 people. The Romanian market is highly promising for Dr.Max, nevertheless Dr.Max sees further development within Europe. The company is becoming a unique European player providing innovative ways to address health and wellbeing applying an omnichannel set up. This will generate significant benefits for patients, pharmacists, suppliers, and employees.

More news

Fortuna leadership update – welcoming new CEO

Jaroslav Haščák returns to Penta’s top management

Jaroslav Haščák, the co-founder of the Penta investment group, returns to the top management of the company after almost four years. With effect from 1 October 2024, he will once again be fully involved in the Investment Committee and the Executive Board, as well as in the management of Penta Group’s corporate portfolio.

Penta opens up to investors after 30 years since its founding

Penta has reported a net profit of €504 million for the financial year 2023, which is the 2nd best result in the Group´s history (after the record numbers achieved in 2021). The Group’s consistent and robust results stem from the strong underlying growth of it’s core portfolio companies.

Continuing to invest into long term growth despite a challenging business environment

Penta has reported a net profit of €483 million for the financial year 2022. The consistent profits generated allow the group to continue to invest significantly into its portfolio of companies with Capital Expenditures totalling €806 million during 2022. Currently the Group employs more than 40,000 people and paid a total of €607 million in income tax and other social contributions.

Penta Real Estate is launching an Architectural and Urban Design competition for a development near the southern bank of the Danube River.

Penta Real Estate is launching an international architectural and urban design competition, the aim of which is to find a future solution and form of development of the area near the southern bank of the Danube river, in the area between Bratislava’s Old Bridge, the Apollo Bridge and the Harbor Bridge. The competition is open, three invited international architectural studios will also participate.

Penta has sold a majority stake in the Empik Group

The current president of the company’s management board, Ewa Szmidt-Belcarz, takes over a controlling stake in the Empik Group.

Penta continues significant investments

Penta has reported a net profit of €570 million for 2021. The group continues to invest significantly into its portfolio of companies with CAPEX totalling €525 million during 2021. Over the next five years, Penta is planning to invest a further €3 billion into both organic development and acquisitions within its existing investment platforms. At the end of 2021, the Group employed more than 41,000 people and paid a total of €496 million in income tax and other social contributions.

Masaryk’s highest point cost 600 million

The reinforced concrete skeleton of the two buildings we are constructing at Masaryk Railway Station in the centre of Prague has reached its highest point. We first presented British architect Zaha Hadid’s multifunctional building project to the public six years ago, and the building itself began to grow along Na Florenci Street in March last year.

See all articles